FACS assay shows that Biotinylated Human OX40 Ligand, Avitag,Fc Tag (OXL-H82F4) can bind to HEK293/Human OX40 / TNFRSF4 / CD134 Stable Cell Line(HEK-ATP053). HEK293/Human OX40 / TNFRSF4 / CD134 Stable Cell Line was red line, Negative control HEK293 cells was grey line(QC tested).
Loaded Biotinylated Human OX40, Avitag,His Tag (Cat. No. TN4-H82E4) on SA Biosensor, can bind Anti-OX40 MAb (Human IgG1) with an affinity constant of 0.115 nM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).
Loaded Biotinylated Human OX40, Avitag,His Tag (Cat. No. TN4-H82E4) on SA Biosensor, can bind Human OX40 Ligand, His Tag (active trimer) (MALS verified) (Cat. No. OXL-H52Q8) with an affinity constant of 0.127 nM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).
| Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
|---|---|---|---|---|---|
| SAR-442970 | SAR-442970 | Phase 1 Clinical | Sanofi | Inflammation | Details |
| SHR-1806 | SHR-1806 | Phase 1 Clinical | Jiangsu Hengrui Medicine Co Ltd, Suzhou Suncadia Biopharmaceuticals Co Ltd | Neoplasms | Details |
| KN-052 | KN-052 | Phase 1 Clinical | Solid tumours | Details | |
| Recombinant human anti-OX40 monoclonal antibody (Livzon Group) | Phase 1 Clinical | Livzon Pharmaceutical Group Inc | Neoplasms | Details | |
| Tavolimab | MEDI-0562 | Phase 1 Clinical | Medimmune | Solid tumours; Head and Neck Neoplasms; Squamous Cell Carcinoma of Head and Neck; Neoplasms, Squamous Cell; Carcinoma, Squamous Cell; Melanoma | Details |
| SL-279252 | TAK-252; SL-279252 | Phase 1 Clinical | Takeda Pharmaceutical Co Ltd, Shattuck Labs Inc | Squamous Cell Carcinoma of Head and Neck; Esophageal Neoplasms; Carcinoma, Renal Cell; Carcinoma, Transitional Cell; Hodgkin Disease; Lymphoma, Large B-Cell, Diffuse; Carcinoma, Non-Small-Cell Lung; Melanoma; Adenocarcinoma | Details |
| Telazorlimab | GBR-830; ISB-830 | Phase 2 Clinical | Glenmark Pharmaceuticals Ltd | Dermatitis, Atopic | Details |
| HFB-3010(HiFiBiO Therapeutics) | HFB-3010; HFB-301001 | Phase 1 Clinical | HiFiBiO Therapeutics | Solid tumours; Carcinoma, Renal Cell; Squamous Cell Carcinoma of Head and Neck; Sarcoma; Uterine Neoplasms; Carcinoma, Hepatocellular | Details |
| INBRX-106 | ES-102; ES102; INBRX-106 | Phase 1 Clinical | Inhibrx | Solid tumours; Head and Neck Neoplasms; Carcinoma, Renal Cell; Stomach Neoplasms; Neoplasms; Carcinoma, Transitional Cell; Carcinoma, Non-Small-Cell Lung; Melanoma | Details |
| BAT-6026 | BAT-6026 | Phase 1 Clinical | Shanghai Cp Guojian Pharmaceutical Co Ltd, Bio-Thera Solutions Ltd | Solid tumours; Neoplasms | Details |
| Revdofilimab | ABBV-368; PR-1628103 | Phase 1 Clinical | Abbvie Inc | Solid tumours; Head and Neck Neoplasms; Triple Negative Breast Neoplasms; Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
| ATOR-1015 | ADC-1015; ATOR-1015 | Phase 1 Clinical | Alligator Bioscience Ab | Solid tumours; Neoplasms | Details |
| Cudarolimab | IBI-101 | Phase 1 Clinical | Innovent Biologics(Suzhou) Co Ltd | Solid tumours; Neoplasms | Details |
| FS-120 | FS-120 | Phase 1 Clinical | F-Star | Neoplasms; Neoplasm Metastasis | Details |
| GSK3174998 | GSK3174998; GSK 3174998; GSK-3174998 | Phase 2 Clinical | Glaxosmithkline Plc | Neoplasms; Multiple Myeloma | Details |
| EMB-09 | EMB-09 | Phase 1 Clinical | Shanghai Epimab Biotherapeutics, Inc | Solid tumours | Details |
| INCAGN-1949 | INCAGN-1949 | Phase 2 Clinical | Agenus Inc, Ludwig Institute For Cancer Research | Solid tumours; Pancreatic Neoplasms; Neoplasms; Neoplasm Metastasis | Details |
| BMS-986178 | BMS-986178 | Phase 1 Clinical | Bristol-Myers Squibb Company | Lymphoma, B-Cell; Lymphoma, B-Cell, Marginal Zone; Solid tumours; Neoplasms; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Waldenstrom Macroglobulinemia; Leukemia, Lymphocytic, Chronic, B-Cell | Details |
| IMG-007 | IMG-007 | Phase 1 Clinical | Hutchmed (China) Ltd | Dermatitis, Atopic | Details |
| Ivuxolimab | PF-8600; PF-04518600 | Phase 3 Clinical | Pfizer Pharmaceuticals Ltd (China) | Solid tumours; Ovarian Neoplasms; Carcinoma; Carcinoma, Renal Cell; Neoplasms; Triple Negative Breast Neoplasms; Prostatic Neoplasms; Breast Neoplasms; Lymphoma, Follicular; Leukemia, Myeloid, Acute; Carcinoma, Non-Small-Cell Lung | Details |
| MEDI-6469 | MEDI-6469; AGX-051 | Phase 1 Clinical | Providence Cancer Center, AgonOx Inc, Astrazeneca Plc, Providence Health & Services | Solid tumours; Liver Neoplasms; Head and Neck Neoplasms; Neoplasms; Breast Neoplasms; Prostatic Neoplasms; Colorectal Neoplasms; Lymphoma; Neoplasm Metastasis; Melanoma | Details |
| Rocatinlimab | KHK-4083; AMG-451 | Phase 3 Clinical | Kyowa Hakko Kirin Co Ltd, Amgen Inc | Abdominal Pain; Inflammatory Bowel Diseases; Gastrointestinal Diseases; Digestive System Diseases; Autoimmune Diseases; Colitis; Colonic Diseases; Colitis, Ulcerative; Dermatitis, Atopic; Intestinal Diseases | Details |
| BGB-A445 | BGB-A445 | Phase 2 Clinical | Beigene Ltd | Solid tumours; Carcinoma, Non-Small-Cell Lung | Details |
| Recombinant human anti-OX40 monoclonal antibody (Eucure Biopharma) | YH-002 | Phase 1 Clinical | Eucure Pharmaceutical Technology (Beijing) Co Ltd | Solid tumours | Details |
This web search service is supported by Google Inc.
A-Z
FLAG
Star Staining
ViruStop
Aneuro
ComboX
ActiveMax
GENPower
ClinMax 
Star Ribbon 
